[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizophrenia-spectrum-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizophrenia-spectrum-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100604229","personalized-metacognitive-training-for-psychosis-a-randomized-controlled-trial-100604229",false,"NCT07146802","Personalized Metacognitive Training for Psychosis: A Randomized Controlled Trial","Towards a Personalized Medicine Approach to Psychological Treatment for Psychosis","PERMEPSY","Inclusion Criteria:\n\n* Adults, 18 - 65 years of age.\n* Patient affiliated to health insurance\n* Inpatients and outpatients with DSM-5 diagnosis of schizophrenia spectrum disorder.\n* Presence of positive symptoms at inclusion (PANSS delusions, suspiciousness or grandiosity ≥3).\n* Stable condition with no expected changes in medication or symptoms during the last 3 months (information from clinical services, note that stable condition includes lack of suicidality).\n* Patient providing informed consent.\n\nExclusion Criteria:\n\n* Having received MCT in the previous year.\n* Neurological disorder, or severe medical condition other than psychosis\n* A score above 5 in the \"Hostility\" and the \"Suspiciousness\" items of the PANSS Positive subscale (to preserve group dynamics).\n* Patient considered by his psychiatrist to be at serious risk of harm to self or others (e.g. previous aggressive or suicidal behaviors)\n* Patient in an exclusion period defined by another research protocol\n* Patient involved in another Investigational Medicinal Product trial\n* Patient under guardianship (i.e. French \"tutelle\")\n* Patients deprived of freedom because of a judicial measure.","ALL","18 Years","65 Years",{"count":21,"type":22},51,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to compare the efficacy of classical Metacognitive Training (MCT) and personalized Metacognitive Training (P-MCT) for individuals with psychosis. MCT is a psychoeducational program derived from cognitive-behavioral therapy (CBT) that targets cognitive biases associated with psychotic symptoms. The goal is to assess which intervention is more effective to improve the overall functioning of individuals with psychosis. The study will use machine learning to personalize the treatment approach and evaluate its impact on clinical symptoms, cognitive functions, and quality of life.",[28],"Schizophrenia Spectrum Disorder","RECRUITING","2026-08-18",{"date":32,"type":33},"2026-08-20","ACTUAL",{"date":35,"type":33},"2026-04-03",{"date":37,"type":22},"2027-04-01",{"name":39,"class":40},"University Hospital, Strasbourg, France","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100615294","transcranial-magnetic-stimulation-tms-for-negative-symptoms-in-schizophrenia-spectrum-disorders-100615294","NCT07290738","Transcranial Magnetic Stimulation (TMS) for Negative Symptoms in Schizophrenia Spectrum Disorders","TMS for Negative Symptoms in Schizophrenia Spectrum Disorders","Inclusion Criteria:\n\n* Ability to give written informed consent\n* Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.\n* Is currently under the care of a licensed primary care provider or mental healthcare provider (e.g., psychiatrist, psychologist, nurse practitioner, licensed clinical social worker).\n* Have negative symptoms as determined by BNSS score of 20 or more.\n* Agrees to provide written permission, as requested, to allow any and all forms of communication between the investigators and study staff and any health care provider who currently provides and\u002For has provided service to the subject within two years of study enrollment\n\nExclusion Criteria:\n\n* Persons with a first-degree relative with inherited epilepsy, seizure disorder, or seizures or persons who answer \"yes\" to any of the parts (A. - G.) of Question 3 of an epilepsy screening questionnaire.\n* Taking \\> 400 mg clozapine\u002Fday and not on anti-seizure medication(s) with sufficient dose.\n* Failed TMS screening questionnaire.\n* Significant alcohol or other drug use (substance dependence within the recent months) or positive urine toxicology screen for substance not prescribed other than nicotine or marijuana dependence.\n* Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, stroke, Central nervous System (CNS)infection or tumor, other significant brain neurological conditions.\n* Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.\n* History of head injury with loss of consciousness over 10 minutes; history of brain surgery\n* 0 Cannot refrain from using alcohol and\u002For marijuana 24 hours or more prior to experiments.\n* Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive pregnancy test) or has had unprotected sexual intercourse without birth control in the last 4 weeks.\n* Moderate-High Risk of suicide according to the Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (i.e. answers YES to Question 2 and NO to Question 6 (Moderate risk); or answers YES to Questions 3 (Moderate risk), 4, 5, or 6 (High risk) or in the clinical judgement of the investigator or the study psychiatrist.\n* History (or family history) of deep vein thrombosis.","60 Years",{"count":51,"type":22},20,[25],"The purpose of this study is to determine if repetitive transcranial magnetic stimulation (rTMS) applied to angular gyrus (AG) will improve negative symptoms and\u002For other psychosis symptoms in schizophrenia spectrum disorders (SSD) patients compared with prefrontal cortex (PFC) or sham.",[28],"2026-03-23",{"date":57,"type":33},"2026-03-24",{"date":59,"type":33},"2026-03-13",{"date":61,"type":22},"2030-11-30",{"name":63,"class":40},"The University of Texas Health Science Center, Houston"]